Pharmaceutical giant Johnson & Johnson (NYSE: JNJ) has agreed to pay over $2.2 billion to settle criminal and civil claims related to the marketing of antipsychotic drug Risperdal and other medications. The lawsuits alleged that JNJ marketed the medications for off-label uses. The Justice Department also said that the company paid kickbacks to a major pharmacy. JNJ has agreed to pay $485 million in criminal fines and forfeiture and $1.72 billion in civil settlements with the federal government and states.
Recent Comments